These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The key points in intravenous chemotherapy and intra-arterial chemotherapy on retinoblastoma treatment].
    Author: Zhao JY, Zhang CY.
    Journal: Zhonghua Yan Ke Za Zhi; 2017 Aug 11; 53(8):566-569. PubMed ID: 28851195.
    Abstract:
    Intravenous chemotherapy and intra-arterial chemotherapy (IAC) both are the first-line treatment for retinoblastoma (RB) in clinical. There is a controversy on if intra-arterial chemotherapy can substitute the intravenous chemotherapy due to its high eye salvage rate in retinoblastoma therapy. The advantages and disadvantages of these two therapies were retrospectively reviewed here to suggest an individualized and comprehensive regimen for getting the proximal results for retinoblastoma afflicted children. (Chin J Ophthalmol, 2017, 53: 566-569). 经静脉全身化学治疗和经眼动脉灌注化学治疗（IAC）均是临床视网膜母细胞瘤（RB）的一线治疗方法。但是，随着IAC方法在眼球保存率方面的优势不断突显，其是否可以取代经静脉全身化学治疗方法存在诸多争议。本文通过回顾两种治疗方法各自的优缺点，提出应针对不同RB患儿采用个性化综合治疗方案，以期达到最佳的治疗效果。（中华眼科杂志，2017，53：566-569）.
    [Abstract] [Full Text] [Related] [New Search]